MBP and myeloid sarcoma: Importantly, antibodies from approximately 80% of MS patients were able to degrade the encephalitogenic MBP peptide 81–10330; in contrast, this ability was present in antibodies from only 9% of patients with other neuronal disorders and was entirely absent in antibodies from healthy donors.